Fermer le menu


Member of Lyonbiopole


MSInsight, a French healthtech company, is empowering the fight against cancer by revealing actionable information from the genome. We are committed to developing a portfolio of state-of-the-art diagnostic solutions for Microsatellite Instability (MSI) status.

MSI has been shown as an indicator of treatment response, especially for immune checkpoint inhibitors and as an important pan-cancer biomarker.

We aim at proposing bioinformatic tools for delivering insights on microsatellite mutational variations, using Next-Generation Sequencing data. Our flagship product, MSI-Care, will be available as a robust diagnostic, pronostic, theranostic assistant for improving patient care.


Application market: Oncology

Type of activity: Diagnostics, E-Health, Medical device

Technologies: AI, (Bio) Informatics & software, NGS & Omics technologies

Created on feb. 24th, 2022 - 4 employees



55 ter Avenue René Cassin 69009 LYON



Vous devez être connecté et membre de Lyonbiopôle pour voir les contacts.